Equities

Quantum-Si Inc

QSI:NMQ

Quantum-Si Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.06
  • Today's Change0.06 / 6.00%
  • Shares traded691.10k
  • 1 Year change-49.52%
  • Beta2.9082
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.

  • Revenue in USD (TTM)1.70m
  • Net income in USD-89.35m
  • Incorporated2020
  • Employees159.00
  • Location
    Quantum-Si Inc29 Business Park DriveBRANFORD 06405United StatesUSA
  • Phone+1 (203) 458-7100
  • Fax+1 (302) 636-5454
  • Websitehttps://www.quantum-si.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Prelude Therapeutics Inc0.00-129.85m140.31m128.00--0.5898-----1.80-1.800.004.320.00----0.00-51.44-47.21-55.69-51.07------------0.0028-------5.54--46.03--
aTyr Pharma Inc588.00k-57.90m141.74m56.00--1.74--241.05-0.9047-0.90470.00921.080.0049--0.403410,500.00-48.51-45.45-53.89-52.74-----9,846.26-784.19----0.0202---96.60---11.14--47.98--
Outlook Therapeutics Inc0.00-94.05m141.93m24.00---------8.12-8.120.00-3.570.00----0.00-205.48-214.69---1,843.48-------3,043.92---26.89--------10.70------
Century Therapeutics Inc2.04m-131.39m144.02m152.00--0.6472--70.53-2.04-2.040.0312.630.0049----13,434.21-31.52---33.04-------6,434.23------0.00---57.01---4.38------
CervoMed Inc9.65m-5.04m144.19m8.00--2.89--14.94-0.4796-0.47961.556.060.2803----1,206,660.00-14.64-53.67-15.71-58.89-----52.24-949.54----0.00------86.07------
Fennec Pharmaceuticals Inc48.89m2.74m144.73m36.00135.99--52.922.960.03890.03891.75-0.04971.181.216.63--6.62-73.437.70-84.3295.55--5.59-383.287.751.871.05--1,284.50--32.34------
ProQR Therapeutics NV20.88m-24.04m145.39m157.00--4.09--6.96-0.2956-0.29560.25660.43520.1406----132,979.00-15.98-35.51-20.63-40.51-----113.62-926.31----0.3687--118.5110.5856.35--34.45--
Invivyd Inc2.26m-203.84m145.72m94.00--1.04--64.36-1.80-1.800.01991.180.0092--1.1324,085.11-82.73---96.25--96.11---9,003.40--4.57--0.00------17.68------
Repare Therapeutics Inc68.68m-68.52m148.56m179.00--0.7294--2.16-1.63-1.631.614.800.2558--6.34383,703.90-25.52-23.40-30.30-26.37-----99.76-162.76----0.00---61.21---222.91--27.16--
Quantum-Si Inc1.70m-89.35m150.90m159.00--0.6467--88.66-0.6302-0.63020.0121.640.00570.23213.6810,704.40-29.89---30.99--53.41---5,249.65--20.13--0.00------27.55------
Acumen Pharmaceuticals Inc0.00-64.86m155.01m51.00--0.6354-----1.11-1.110.004.060.00----0.00-27.82---29.32--------------0.1075-------22.20------
Adverum Biotechnologies Inc0.00-99.86m156.01m121.00--0.9285-----7.99-7.990.008.080.00----0.00-40.33-36.39-46.64-39.04-------5,279.60----0.00----17.4324.18---0.0247--
Actuate Therapeutics Inc0.00-27.77m156.52m6.00---------1.45-1.450.00-0.7114------0.00-------------------134.25---------22.74------
Achieve Life Sciences Inc0.00-27.54m156.60m22.00--3.70-----1.10-1.100.001.230.00----0.00-58.78-86.31-71.94-119.59-----------11.790.294------29.60---14.51--
P3 Health Partners Inc1.40bn-69.48m159.51m400.00--0.4323--0.1137-0.5821-0.582111.561.031.56--10.973,507,143.00-20.51---110.70--0.62230.1781-13.17-56.93---9.670.2686--20.6770.5878.61---11.20--
Seres Therapeutics Inc374.00k-162.11m160.00m233.00------427.81-1.18-1.180.0027-0.57420.001--0.02861,605.15-44.53-41.51-59.82-54.13-----43,343.58-170.140.889-17.646.65--1,672.2434.9154.54--32.72--
Data as of Sep 19 2024. Currency figures normalised to Quantum-Si Inc's reporting currency: US Dollar USD

Institutional shareholders

31.43%Per cent of shares held by top holders
HolderShares% Held
ARK Investment Management LLCas of 30 Jun 202412.41m10.14%
Nikko Asset Management Americas, Inc.as of 30 Jun 20247.86m6.42%
BlackRock Fund Advisorsas of 30 Jun 20246.17m5.04%
The Vanguard Group, Inc.as of 30 Jun 20244.87m3.98%
SSgA Funds Management, Inc.as of 30 Jun 20242.37m1.94%
Geode Capital Management LLCas of 30 Jun 20242.17m1.77%
Jacobs Levy Equity Management, Inc.as of 30 Jun 2024942.76k0.77%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024782.19k0.64%
BlackRock Advisors LLCas of 30 Jun 2024480.88k0.39%
Bridgeway Capital Management LLCas of 30 Jun 2024406.70k0.33%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.